HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings

Celcuity, Inc. (NASDAQ:CELC) – Analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Celcuity in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.22) for the quarter, down from their prior forecast of ($1.17). HC Wainwright currently has a “Buy” rating and a $155.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($3.76) per share. HC Wainwright also issued estimates for Celcuity’s Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($4.12) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.95) EPS.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10.

CELC has been the topic of several other reports. Wells Fargo & Company decreased their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Leerink Partners set a $155.00 target price on shares of Celcuity in a report on Tuesday, June 2nd. Guggenheim restated a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Citizens Jmp upped their price target on shares of Celcuity from $160.00 to $177.00 and gave the company a “market outperform” rating in a research note on Wednesday. Finally, Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research note on Thursday, May 28th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Price Performance

Shares of Celcuity stock opened at $88.38 on Friday. The firm has a market cap of $4.31 billion, a PE ratio of -22.66 and a beta of 0.16. The stock has a 50 day moving average of $108.17 and a 200 day moving average of $110.80. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity has a 12 month low of $13.47 and a 12 month high of $151.02.

Institutional Trading of Celcuity

A number of institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. Parallel Advisors LLC purchased a new position in shares of Celcuity during the 1st quarter worth about $38,000. Finally, Meeder Asset Management Inc. bought a new position in Celcuity during the 4th quarter valued at about $42,000. 63.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

More Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity won FDA approval for REVTORPYK in advanced HR+/HER2- breast cancer, a key catalyst that validates the drug and could support future revenue growth. Celcuity gains FDA approval for closely watched breast cancer drug
• Positive Sentiment: Several recent coverage items highlight optimism that the approval could position Celcuity as a more attractive oncology asset, even raising speculation it could draw interest from larger pharmaceutical companies. With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
• Neutral Sentiment: HC Wainwright kept a Buy rating and $155 price target, but trimmed earnings estimates for FY2026 and multiple 2027 periods, reflecting a more cautious near-term profit outlook despite the long-term story remaining intact.
• Negative Sentiment: Investor concern is building around commercialization timing and rollout execution, which has led some reports to say the FDA approval was not enough to offset questions about launch speed and market uptake. Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Celcuity investors, adding a legal overhang that can pressure sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. – CELC

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.